Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record.

TOPOISOMERASE II INHIBITOR‐RELATED ACUTE MYELOID LEUKAEMIA

Open access
Pui, Ching‐Hon, Relling, Mary V. · 2000 · British Journal of Haematology

Abstract

In the late 1980s, we and colleagues described unique cases of treatment-related acute myeloid leukaemia (AML) in patients who had received intensive chemotherapy, including the epipodophyllotoxins, for acute lymphoblastic leukaemia (ALL) or solid tumours ( Ratain et al, 1987 ; DeVore et al, 1989 ; Pui et al, 1989 , 1990; Albain et al, 1990 ; Pedersen-Bjergaard et al, 1990 ; Prieto et al, 1990 ). A causative role of the epipodophyllotoxins was suspected but could not be established unequivocally. Thus, the terms secondary AML and therapy-related AML were used to describe these cases. By 1991, the leukaemogenic potential of the epipodophyllotoxins was firmly established ( Pui et al, 1991 ), leading to the term epipodophyllotoxin-related AML ( Pui, 1991; Whitlock et al, 1991 ). It has since been recognized that other topoisomerase II inhibitors, such as the anthracyclines (doxorubicin, 4-epi-doxorubicin), mitoxantrone, dactinomycin and dioxypiperazine derivatives (e.g. bimolane), can also induce AML with similar features, albeit at a lower frequency ( Andersson et al, 1990 ; Pui, 1991; Pedersen-Bjergaard et al, 1992 ; Xue et al, 1992 ; Sandoval et al, 1993 ; Pedersen-Bjergaard & Rowley, 1994; Smith et al, 1996 ). Collectively, these cases have been classified as topoisomerase II inhibitor-related leukaemia ( Ratain & Rowley, 1992; Pedersen-Bjergaard et al, 1993 ; Sandoval et al, 1993 ; Smith et al, 1995 ). We review here the pathogenesis, clinical and biological characteristics, risk factors and treatment responsiveness of this complication. Acute myeloid leukaemia after topoisomerase II inhibitor therapy can be distinguished from other therapy-related tumours by its unique molecular signature: balanced translocations involving the MLL ( mixed- lineage leukaemia or myeloid/ lymphoid leukaemia) gene on chromosome 11, band q23 ( DeVore et al, 1989 ; Pui et al, 1989 , 1991; Pedersen-Bjergaard et al, 1990 ; Ratain & Rowley, 1992; Felix et al, 1993 ; Super et al, 1993 ). The MLL gene, also referred to as ALL-1, HRX and HTRX1, encompasses more than 30 exons spread over approximately 100 kb of genomic DNA and is highly conserved among species ( Cimino et al, 1991 ; Ziemin-van der Poel et al, 1991 ; Gu et al, 1992a ; Downing & Look, 1996; Rasio et al, 1996 ). The homologue in Drosophila, the HRX or HTRX (trithorax) gene, is critical in segmental development ( Tkachuk et al, 1992 ; Parry et al, 1993 ). MLL is thought to act as a transcription factor, as it displays zinc finger and AT-hook domains, as well as regions of homology to DNA methyltransferases, all of which suggest a direct interaction between MLL and DNA ( Zeleznik-Le et al, 1994 ; Downing & Look, 1996). The MLL gene is rearranged in up to 70% of de novo leukaemias in infants ( Downing & Look, 1996). Such alterations can be found in both ALL and AML, with the t(4;11) more commonly associated with the former disease and the t(11;19) and t(9;11) with the latter ( Ziemin-van der Poel et al, 1991 ; Thirman et al, 1993 ; Downing & Look, 1996). MLL rearrangements have also been associated with 'mixed-lineage' leukaemia, in which the blast cells display both myeloid and lymphoid characteristics. Thus, it is presumed that MLL rearrangements in treatment-related leukaemias may originate in a pluripotent haematopoietic stem cell. Interestingly, the vast majority (> 90%) of therapy-related leukaemias with MLL rearrangements have a myeloid phenotype ( Hunger et al, 1992 ), whereas myeloid and lymphoid phenotypes are evenly distributed among de novo leukaemia cases with these abnormalities. One explanation is that, whereas lymphoid progenitors may sustain mutagenic effects as often as myeloid progenitors, the emerging ALL clones are more drug responsive and thus more easily eradicated than those of myeloid origin by the antileukaemia agents that patients are receiving. Consistent with this notion is the disproportionately high number of cases of secondary ALL with rearranged MLL genes that occur in patients originally treated for diseases other than ALL ( Hunger et al, 1992 ; Pratt & Pui, 1992). Alternatively, myeloid progenitors may be more susceptible than lymphoid progenitors to the mutagenic effects of topoisomerase II inhibitors. The critical physiological role of the MLL gene is indicated by the lethality of its deletion in mice ( Yu et al, 1995 ; 1998) and by its requirement for normal cell proliferation and differentiation during haematopoiesis ( Fidanza et al, 1996 ; Hess et al, 1997 ). Moreover, all chimeric mice with the MLL/AF9 transgene developed myeloid leukaemia at 4–12 months after transduction ( Corral et al, 1996 ). This delayed onset has led to speculation that mutagenic events subsequent to MLL rearrangement are needed to induce a leukaemic phenotype. Whatever the mechanism, MLL rearrangement (or at least MLL/AF9 fusion) appears to be a pivotal event in the genesis of therapy-related AML, rather than merely a genetic epiphenomenon. Much research has

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2000.01843.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 185

Metadata

Authors
Pui, C., & Relling, M. V.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2000-04
Volume
109
Issue
1
Pages
13-23
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1999533317
Cited by
185
References
0
FWCI
7.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TOPOISOMERASE II INHIBITOR‐RELATED ACUTE MYELOID LEUKAEMIA. https://app.cochat.ai/papers/10.1046/j.1365-2141.2000.01843.x
The paper
Pui, C., & Relling, M. V. (2000). TOPOISOMERASE II INHIBITOR‐RELATED ACUTE MYELOID LEUKAEMIA. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2000.01843.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.